Related by context. All words. (Click for frequent words.) 84 statistically significant p = 73 placebo p 71 placebo p = 71 statistical significance p 69 achieved statistical significance 69 P ≤ 67 P = .# 66 HIV RNA 66 p = 65 statistically significant 65 lumbar spine BMD 65 Xalatan R 65 μmol L 64 creatinine ratio 64 undetectable HBV DNA 64 p = #.# [002] 64 mg p = 64 p = .# [002] 64 serum urate 64 #.#/#.# mmHg [001] 64 log# 63 mg QD 63 p = #.# [004] 63 HBeAg seroconversion 63 sUA 63 p ≤ 63 mg kg Hematide 62 linaclotide treated 62 CI -#.# 62 MADRS score 62 Hazard Ratio HR 62 oxycodone CR 62 mg ustekinumab 62 p = #.# [003] 62 lispro 62 Doxil ® 62 posttreatment 62 HBeAg 62 binary restenosis 62 biochemical relapse 62 serum estradiol 62 tolterodine ER 62 % CI #.#-#.# [001] 61 % CI #.#-#.# [003] 61 achieved ACR# 61 x ULN 61 mg kg dose 61 confidence interval CI 61 PSA nadir 61 log# copies mL 61 baseline HbA1c 61 serum HBV DNA 61 confidence interval #.#-#.# 61 nonsignificant 61 lopinavir r arm 61 tirofiban 61 lopinavir r 61 alanine aminotransferase 61 -#.# ± [002] 61 mmHg p = 61 mcg BID 61 pmol L 61 HBeAg negative patients 60 transaminase elevations 60 pCR 60 hsCRP levels 60 titrated glipizide 60 methotrexate monotherapy 60 % Confidence Interval 60 locoregional recurrence 60 serum phosphorus 60 elevated ALT 60 statistically significant reduction 60 ULORIC 60 T2 lesion volume 60 highly emetogenic 60 plasma leptin 60 clodronate 60 dapagliflozin plus 60 serum phosphate 60 HbA 1c levels 60 certolizumab 60 μg mL 60 lactate dehydrogenase 60 lactate dehydrogenase LDH 60 alanine aminotransferase ALT 60 #mg BID [001] 60 timepoint 60 % CI #.#-#.# [006] 60 mcg kg 60 mL/min/#.# m 2 60 HOMA IR 60 Crohn Disease Activity 60 mg/m2 dose 60 postintervention 60 statistical significance p = 60 -#.# mg dL [002] 59 kappa = 59 plus methotrexate 59 serum concentrations 59 #.#/#.# mm Hg [003] 59 lamivudine refractory patients 59 HBV DNA 59 virologic response 59 chlorambucil 59 4mg/kg 59 CCyR 59 tipranavir r 59 #μg [002] 59 liver histology 59 annualized relapse 59 pg mL 59 IFN α 59 Secondary endpoints included 59 TMC# r 59 neutrophil counts 59 mcg QD 59 ritonavir boosted 59 troponin T 59 SBM frequency 59 QTcF 59 leukocyte count 59 IU mL 59 IOP lowering 59 colorectal adenoma 59 glycosylated hemoglobin HbA1c 59 intima media thickness 59 REYATAZ r arm 59 FOLFOX4 59 XIENCE V PROMUS Stent 59 -#.# mg dL [001] 59 mg TID 59 ACR# response 59 #.#mg/dL 59 CsA 59 placebo fluoxetine 59 definite stent thrombosis 59 serum ALT 59 mcg Albuferon 59 evaluable 59 plasma pharmacokinetics 59 μg L 59 thyroglobulin 59 log# IU mL 59 % CI #.#-#.# [008] 59 laboratory abnormalities 58 nmol L 58 ropivacaine 58 tHcy 58 IPSS 58 mEq L 58 Index CDAI 58 SVR# 58 μg kg 58 incontinence episodes 58 univariate analysis 58 reinfarction 58 umol L 58 pg ml 58 aspartate aminotransferase AST 58 insulin detemir 58 nmol l 58 PASI scores 58 LEXIVA r 58 baseline LDH 58 #mg BID [003] 58 Serum creatinine 58 tipranavir ritonavir 58 unfractionated heparin 58 HbA1c levels 58 mmHg diastolic 58 EpCAM expression 58 abacavir lamivudine 58 glycated hemoglobin HbA1c 58 haematologic 58 NPH insulin 58 #mg/day [001] 58 periprocedural 58 serum creatinine levels 58 infliximab monotherapy 58 morphometric vertebral fractures 58 nondiabetic patients 58 nicardipine 58 TPV r 58 AST ALT 58 mg d 58 5-FU/LV 58 interobserver reliability 58 mg qd 58 mmol l 58 HbA 1c 58 CIMZIA ™ 58 aspartate aminotransferase 58 GERD symptom 58 serum uric acid 58 % CI #.#-#.# [002] 58 serum urate levels 58 AUA Symptom Score 58 serum potassium 58 serum phosphorous 58 apolipoprotein B 57 endometrial thickness 57 prolonged QT interval 57 atorvastatin #mg 57 atazanavir ritonavir 57 % CI #.#-#.# [007] 57 fosamprenavir 57 mesalamine granules 57 budesonide pMDI 57 CIMZIA TM 57 recurrent venous thromboembolism 57 Cmax 57 LPV r 57 platelet reactivity 57 serum cortisol 57 placebo 57 prespecified 57 unfractionated heparin UFH 57 hemoglobin A1c HbA1c 57 lumbar spine bone 57 virologic 57 virological response 57 febrile neutropenia 57 serum TSH 57 albumin excretion rate 57 copies mL 57 intact parathyroid hormone 57 DAS# CRP 57 urinary N telopeptide 57 Secondary endpoints include 57 bivalirudin monotherapy 57 #mg/day [002] 57 partial remissions 57 virologic responses 57 genotypic resistance 57 transdermal estradiol 57 solifenacin 57 nmol 57 splenectomized 57 prospectively stratified 57 evaluable subjects 57 HDRS 57 ALT normalization 57 μg ml 57 statistically significant improvement 57 TEAEs 57 HbA1C 57 CI #.#-#.# [002] 57 urinary albumin 57 mcg albinterferon alfa 2b 57 ADAS cog 57 TAXUS p value 57 nmol liter 57 serum PTH 57 endoscopic remission 57 lanthanum carbonate 57 salmeterol fluticasone propionate 57 NNRTI resistance 57 LVEF 57 MMSE score 57 colesevelam HCl 57 isoproterenol 57 UGT#A# * 57 APTIVUS r 57 protein excretion 57 eplerenone 57 -#.# p = 57 CC genotype 57 YMRS 57 virologic failure 57 mcg mL 57 MBq 57 interobserver agreement 57 tertile 57 mg dose 57 ertapenem 57 p = NS 57 Pegasys plus Copegus 57 noninferiority 57 dose proportionality 57 lymphocyte count 57 low dose Iluvien 57 recurrent glioblastoma multiforme 57 serum retinol 57 sustained virologic response 57 relapsed MM 57 seroprotection 57 ng dl 57 methacholine challenge 57 Lucentis monotherapy 56 darunavir ritonavir 56 dose atorvastatin 56 ug mL 56 serum aminotransferase levels 56 NIHSS 56 ug dose 56 PRADAXA #mg 56 interquartile range 56 ezetimibe simvastatin 56 NIH CPSI 56 dalteparin 56 Ceplene/IL-2 56 attain statistical significance 56 oxycodone IR 56 serum calcium 56 r2 = 56 saline placebo 56 intravenous dosing 56 atheroma volume 56 complete cytogenetic response 56 intracranial hemorrhage ICH 56 advanced adenomas 56 glycated hemoglobin levels 56 multivariable adjustment 56 Pharmacokinetics PK 56 DAS# remission 56 r = 56 leukopenia 56 mRNA expression 56 plasma HCV RNA 56 Kaplan Meier analysis 56 SUVmax 56 preoperative PSA 56 ejection fractions 56 antibody titer 56 oral allopurinol 56 hemoglobin Hb 56 dose clopidogrel 56 Pharmacokinetic 56 anti HBs 56 fasting insulin 56 demonstrated statistically significant 56 serum IGF 56 multivariable analysis 56 CR nPR 56 caspofungin 56 aminotransferase levels 56 Histologic 56 fluticasone salmeterol 56 anemia hemoglobin 56 FDG uptake 56 Ki# 56 corticosteroid dose 56 HbA1c 56 median PFS 56 Psoriasis Area 56 receiving VICTRELIS 56 ARB telmisartan 56 response CCyR 56 DAS# [002] 56 Brief Psychiatric 56 advanced adenoma 56 comparator arm 56 adefovir 56 urate lowering therapy 56 CK MB 56 EDSS scores 56 DAS# scores 56 isoprostane 56 Montgomery Asberg Depression 56 elevated creatinine 56 -#.# log# copies mL 56 fructosamine 56 fasting plasma glucose 56 tiotropium 56 locoregional disease 56 cTnT 56 treatment emergent adverse 56 HbA1C levels 56 hip BMD 56 TIMP 1 56 plasma creatinine 56 postprocedure 56 pooled comparator 56 HRCT 56 carotid IMT 56 octreotide LAR 56 clinically meaningful improvement 56 peginterferon alfa 2b 56 statin monotherapy 56 virological failure 56 TAXUS Express Stent 56 mmol kg 56 invasive carcinomas 56 HBeAg positive patients 56 pT3 56 XIENCE V demonstrated 56 -#.# log# 56 hematological parameters 56 elevated LDH 56 viral kinetics 56 serum calcium levels 56 elevated troponin 56 teriflunomide 56 transaminases 56 urinary excretion 56 euthyroid 56 demonstrated clinically meaningful 56 iodixanol 56 median survivals 56 PaO 2 56 DOXIL 56 NMIBC 56 #ug [001] 56 HAQ DI 56 HBV DNA levels 56 Secondary endpoints 56 Hazard Ratio = 56 baseline A1C 56 ketorolac 56 nadroparin 56 #mg doses [002] 55 composite endpoint 55 BMS p = 55 latanoprost 55 oblimersen 55 nadolol 55 #.#ng/ml 55 symptom exacerbation 55 serum testosterone 55 Aptivus ® 55 mmol L. 55 nonsignificant difference 55 radiotherapy RT 55 PREZISTA r 55 ADAS Cog 55 log# reduction 55 lipid parameters 55 macroalbuminuria 55 WOMAC scores 55 statistically nonsignificant 55 favorable pharmacokinetic profile 55 A1c levels 55 grade cervical intraepithelial 55 cTnI 55 everolimus eluting stents 55 8mg/kg 55 PSADT 55 desvenlafaxine succinate 55 ATACAND 55 SGPT 55 detectable HCV RNA 55 LS BMD 55 doxorubicin docetaxel 55 ADCS CGIC 55 posaconazole 55 spontaneous bowel movements 55 hepatic enzymes 55 paresthesias 55 iPTH 55 microgram kg 55 ruboxistaurin 55 oral rivaroxaban 55 ACR# responses 55 mutated KRAS 55 oral olanzapine 55 mmol L 55 HCV RNA 55 ximelagatran 55 mcg dL 55 TT genotype 55 discontinuations due 55 FOLPI 55 racemic albuterol 55 ALVESCO 55 μg g 55 plasma folate 55 GOUT 55 pharmacodynamic PD 55 mm Stent 55 epoetin alpha 55 TDF FTC 55 HES CEL 55 CI = 55 tolvaptan 55 posttransplant 55 exhaled NO 55 #q# deletion syndrome 55 bronchoalveolar lavage 55 oxcarbazepine 55 myeloperoxidase 55 dysuria 55 CANCIDAS 55 plasma uric acid 55 hypoglycemic events 55 estimated glomerular filtration 55 creatinine clearance 55 ALT flares 55 alteplase 55 Primary endpoints 55 serum prostate 55 CIN2 + 55 eGFR 55 LEXIVA 55 urodynamic 55 antihypertensive therapy 55 tapentadol ER 55 pentoxifylline 55 mg dL 55 specific antigen PSA 55 nonresponders 55 SGRQ 55 FluCAM 55 ug ml 55 nmol L. 55 sweat chloride 55 Navelbine 55 ACR# ACR# 55 serum albumin 55 bezafibrate 55 resected pancreatic cancer 55 pleural fluid 55 mg Proellex 55 urinary calcium 55 serum parathyroid hormone 55 CR CRu 55 noninferior 55 ng dL 55 moderately emetogenic 55 serum lipid levels 55 eosinophil count 55 achieved CCyR 55 BPH Symptom Score 55 achieved mucosal healing 55 Flu Cy 55 #ng/ml 55 Hazard Ratio 55 glulisine 55 nonfatal MI 55 Viral load 55 HGPIN 55 efavirenz EFV 55 mmHg p 55 undetectable HCV RNA 55 % CI #.#-#.# [004] 55 endometrial hyperplasia 55 baseline Hb 55 AUC0 55 CrCl 55 sustained virological response 55 salmeterol HFA MDI 55 Baseline characteristics 55 EURIDIS 55 postdose 55 experienced virologic failure 55 Ishak fibrosis score 55 PANSS scores 55 severe neutropenia 55 undetectable viral load 55 receiving highly emetogenic 55 tumor histology 55 UACR 55 ANOVA 55 Pharmacodynamic 55 fasting plasma glucose FPG 55 highest tertile 55 alkaline phosphatase 55 liver transaminases 55 prospectively defined 55 serum magnesium 55 virologic breakthrough 55 achieving PASI 55 microg 55 ‰ ¥ 55 Rating Scale MADRS 55 lymphovascular invasion 55 hematologic toxicity 55 normotensive 55 bronchodilation 55 Tolerability 55 liver metastasis 55 serum CRP 55 CIMZIA TM certolizumab pegol 55 3mg/kg 55 cilostazol 55 #mg/kg [002] 55 abciximab 55 chloride secretion 54 biopsy Gleason 54 ADHD Rating Scale 54 patients undergoing CABG 54 dose cohort 54 uM 54 #Gy 54 idraparinux 54 timolol 54 Apidra ® 54 preintervention 54 dose dependently 54 serum lipid 54 serum leptin 54 CK # plasma concentrations 54 biochemical recurrence 54 progression TTP 54 mucosal healing 54 rosuvastatin #mg 54 regression coefficient 54 #mg QD [001] 54 intracoronary 54 patients evaluable 54 #mm Hg 54 mCi kg 54 prostatic adenocarcinoma 54 dosing cohort 54 histological subtype 54 tapentadol IR 54 MACCE 54 bosentan 54 diameter stenosis 54 sirolimus stent 54 mg BID 54 ovarian carcinoma 54 viremia 54 IgG antibody 54 HAM D 54 pegylated liposomal doxorubicin 54 immunoreactivity 54 severe hypoglycemic 54 serum bilirubin 54 sd = 54 erythrocyte sedimentation rate 54 g dL 54 avosentan 54 #.#,#.# [002] 54 placebo dexamethasone 54 #ug [002] 54 creatine kinase 54 pharmacologically relevant 54 ARCALYST ® 54 ug kg 54 homozygotes 54 CSBM 54 mcg doses 54 serum BDNF 54 LV ejection fraction 54 lymphopenia 54 inflammatory lesions 54 angiographic restenosis 54 chlorthalidone 54 KRAS mutations occur 54 postoperative complication 54 df = 54 Alzheimer Disease Assessment 54 ≥ 54 #mg dose [002] 54 paclitaxel eluting stents 54 transaminase 54 lymph node metastasis 54 intravenous bisphosphonates 54 leucopenia 54 BARACLUDE ® 54 rapid virologic response 54 HCV genotype 54 intraobserver 54 thromboembolic 54 serum sodium 54 hormone receptor negative 54 aspirin clopidogrel 54 multivariate Cox 54 spine BMD 54 Vancocin p = 54 hematologic parameters 54 headache nasopharyngitis 54 urine albumin 54 mg XP# 54 Free Survival PFS 54 intravascular hemolysis 54 hydroxymethyl coenzyme 54 coinfected 54 ziprasidone 54 FOLFIRI 54 T2 lesions 54 complete cytogenetic 54 g dl 54 neutrophil count 54 alanine transaminase 54 oral levofloxacin 54 partial thromboplastin 54 oral FTY# 54 p = ns 54 hypokalemia 54 bovine thrombin 54 CFQ R 54 antiretroviral naïve 54 coinfected patients 54 primary patency 54 VAPRISOL 54 ara C 54 eculizumab therapy 54 μg 54 hypogonadal 54 norethindrone 54 plasma glucose 54 serum homocysteine 54 hyperinsulinemic euglycemic clamp 54 biphasic insulin aspart 54 statistically significant differences 54 Pharmacokinetic parameters 54 steroid dexamethasone 54 paraprotein 54 Stent p = 54 melphalan prednisone 54 % tretinoin Gel 54 EXJADE 54 glomerular filtration 54 plus dexamethasone 54 FOLFOX6 54 ABCB1 54 INCB# [003] 54 mcg ml 54 mucinous 54 IU ml 54 confidence intervals CIs 54 glycated hemoglobin 54 aPTT 54 IELT 54 serum HCV RNA 54 paricalcitol 54 squamous histology 54 Partial Response 54 administered subcutaneously 54 #.#-#.# p = 54 bolus dose 54 antibody titers 54 histologic 54 postop 54 dose dexamethasone 54 dose cytarabine 54 ibandronate 54 hemodynamically significant 54 Severity MSCS score 54 Taxus Stent 54 QTc prolongation 54 amprenavir 54 mg doses 54 cinacalcet 54 Celsentri Selzentry 54 cardiovascular calcification 54 timepoints 54 nephrotoxicity 54 carcinoids 54 univariate 54 Timed Walk 54 thromboembolism 54 nasal symptom 54 micrograms mL 54 splenectomized patients 54 tamsulosin 54 concomitant medications 54 UPDRS scores 54 seropositive patients 54 mol L 54 quetiapine 54 CDAI score 54 gross hematuria 54 eNO 54 IL 1ß 54 peginterferon alfa 2a 54 copies ml 54 incidence ≥ 54 Immunohistochemical staining 54 PegIFN RBV 54 n = 54 Mean Symptom Complex 54 multivariable adjusted 54 nevirapine Viramune 54 neostigmine 54 hypercalcemia 54 receiving ISENTRESS 54 vertebral fracture 54 Plasma concentrations 54 nasopharyngitis 54 hemorrhagic complications 54 QIDS SR 54 statistically significant predictor 54 hemoglobin concentrations 54 gastrointestinal perforation 54 serum GGT 54 sodium nitroprusside 54 SSRI citalopram 54 6MWD 54 mitoxantrone 54 aminotransferases 54 achieved PASI 54 fasting triglyceride levels 54 fasting glucose levels 54 FOSRENOL ® 54 viral load 54 parous women 54 pT2 54 IV bisphosphonates 54 tenofovir emtricitabine 54 C telopeptide 54 depressive symptom 54 β blockers 54 Negative Syndrome 54 fetuin 54 prostate carcinoma 54 adverse reactions incidence 54 anti Xa 54 hyperphenylalaninemia HPA due 54 postmenopausal osteoporotic women 53 C Reactive Protein 53 ddI 53 blood glucose concentrations 53 trough FEV1 53 mineral density 53 BEACOPP 53 N telopeptide 53 piperacillin tazobactam 53 transgene expression 53 tPSA 53 serologically active patients 53 adriamycin 53 Pyratine XR TM 53 Elitek 53 indinavir 53 clevidipine 53 hypophosphatemia 53 ancrod 53 lesional 53 DLTs 53 MDS MPD 53 sirolimus eluting stents 53 mIU L 53 underwent surgical resection 53 mmol 53 CSBMs 53 urinary calcium excretion 53 angiographic outcomes 53 HAM D# scores 53 Hb A1c 53 arterial thromboembolic events 53 Score DAS# 53 #mg dose [001] 53 tenecteplase 53 EDSS score 53 ecchymosis 53 candesartan cilexetil 53 prespecified secondary 53 Q2W 53 intraocular inflammation 53 gastric pH 53 idarubicin 53 pegaptanib 53 micafungin 53 infarct size 53 serum PSA 53 unresectable HCC 53 urate lowering 53 μg liter 53 dobutamine 53 AUCs 53 MoxDuo TM IR 53 Non inferiority 53 hydroxyvitamin D levels 53 severe hypersensitivity reactions 53 Lupuzor ™ 53 mg BID dose 53 BENICAR HCT 53 autologous SCT 53 Pred Forte 53 glomerular filtration rate 53 rho = 53 DAPT 53 NEVO ™ 53 OGTT 53 SCIg 53 estimated GFR 53 REYATAZ ritonavir 53 stent binary restenosis 53 Thal Dex 53 plasma concentrations 53 NATRECOR ® 53 serum triglyceride 53 elastase 53 rizatriptan 53 quetiapine XR 53 ml min 53 fractional shortening 53 Neuropsychiatric Inventory NPI 53 fractional anisotropy 53 completely resected 53 hemoglobin A1c levels 53 seliciclib 53 HAM D# 53 serum IgG 53 viral kinetic 53 CRp 53 adenoma recurrence 53 ribavirin therapy 53 daily subcutaneous injections 53 decitabine 53 mean baseline HbA1c 53 perfusion defect 53 Immunohistochemical analysis 53 hepatic enzyme 53 metformin monotherapy 53 IIIa inhibitors 53 FluCAM arm 53 clinico pathological 53 elevated transaminases 53 oral Hycamtin 53 urinary oxalate 53 moderate renal impairment 53 hemoglobin concentration 53 SSRI SNRI 53 Target Lesion Revascularization TLR 53 RRM1 53 β blocker 53 g mL 53 severe exacerbations 53 interferon ribavirin 53 interobserver 53 bronchodilatory 53 mIU ml 53 inotropic 53 femoral neck BMD 53 metformin hydrochloride 53 Postoperative 53 leuprorelin 53 graft occlusion 53 aOR 53 gout flare 53 ischemia driven 53 cEVR 53 zoledronate 53 multivariate analyzes 53 S#A# [002] 53 mg tid 53 LV dysfunction 53 Ramipril 53 immunostaining 53 abdominal pain abdominal discomfort 53 tiotropium bromide 53 myopathy rhabdomyolysis 53 serum triglycerides 53 lymphocytosis 53 adefovir treated 53 prednisone prednisolone plus 53 nonexposed 53 diuretic chlorthalidone 53 paliperidone ER 53 pharmacodynamic parameters 53 R# #mg BID 53 reactogenicity 53 tipranavir 53 Histological 53 seropositivity 53 mcg kg REBETOL 53 NATRECOR R 53 mild renal impairment 53 oral prednisolone 53 seroconverted 53 lymphocyte counts 53 uncorrected visual acuity 53 retinal thickness 53 pruritus itching 53 refractory ischemia 53 histologically confirmed 53 PREZISTA ritonavir 53 thromboembolic events 53 rimonabant #mg 53 CYT# potent vascular disrupting 53 fluorouracil 53 symptomatic VTE 53 TNF blocker therapy 53 recurrent genital herpes 53 #mg BID [002] 53 Montgomery Åsberg Depression 53 elevated IOP 53 aminotransferase ALT 53 irbesartan 53 cirrhotic 53 flutamide 53 virologic suppression 53 metastatic malignant 53 SpO 2 53 aminotransferase 53 resected tumors 53 ALND 53 TIMP 53 cobiprostone 53 Cronbach alpha 53 ascending dose 53 TLUS 53 kg -1 53 FENO 53 Solid Tumors criteria 53 postoperatively 53 tegaserod 53 sirolimus eluting stent 53 heterozygotes 53 plus MTX 53 mCi 53 GLIADEL R Wafer 53 interferon alfa 2b 53 FOLFIRINOX 53 left ventricular dysfunction